Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Endocrinol Invest ; 44(11): 2485-2492, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33890251

RESUMEN

PURPOSE: Vitamin D (VitD) is a pleiotropic hormone with effects on a multitude of systems and metabolic pathways. Consequently, the relevance of a sufficiently high VitD serum level becomes self-evident. METHODS: A rapid immunofluorescence assay designed for the point-of-care measurement of serum VitD3 solely was tested. Inter- and intra-assay validation, double testing and result comparison with a standardized laboratory method were performed. RESULTS: An overall linear correlation of r = 0.89 (Pearson, 95% CI 0.88-0.92, p < 0.01) between the point of care and the conventional reference assay was registered. Accuracy and precision were of special interest at cut-points (10 ng/ml [mean deviation 1.7 ng/ml, SD 1.98 ng/ml, SE 0.16 ng/ml], 12 ng/ml [MD 0.41, SD 1.89, SE 0.19] and 30 ng/ml [MD - 1.11, SD 3.89, SE 0.35]). Only a slight deviation was detected between the two assays when using fresh (r = 0.91, 95% CI 0.86-0.94, p < 0.01) and frozen serum samples (r = 0.86, 0.82-0.89, p < 0.01). Results remained steady when samples were frozen several times. Inter- and intra-assay validation according to the CLSI protocol as well as multiuser testing showed stable results. CONCLUSION: This novel, innovative, and controlled study indicates that the evaluated rapid point of care VitD assay is reliable, accurate, and suited for clinical practice.


Asunto(s)
Colecalciferol , Técnica del Anticuerpo Fluorescente/métodos , Mediciones Luminiscentes/métodos , Sistemas de Atención de Punto , Deficiencia de Vitamina D , Colecalciferol/análisis , Colecalciferol/sangre , Precisión de la Medición Dimensional , Humanos , Evaluación in Situ Rápida , Reproducibilidad de los Resultados , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/diagnóstico
2.
J Endocrinol Invest ; 43(6): 767-777, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31834613

RESUMEN

PURPOSE: The dual antiproliferative mechanism of mycophenolate appears to be beneficial in Graves' orbitopathy (GO). METHODS: Safety data from the two published mycophenolate trials and the original database of the European Group on Graves' Orbitopathy (EUGOGO) trial were systematically analyzed. Treatment efficacy stratified by individual visual parameters of activity and severity were compared. RESULTS: A total of 129 adverse events (AE) involving 50 patients (29.4%) were noted among all mycophenolate-treated patients. Mycophenolate sodium plus intravenous glucocorticoid (MPS + GC) group of the EUGOGO trial recorded significantly more AE (55.4% versus 4.6% of patients affected) and serious adverse events (SAE) (12.5% versus 0%) than mycophenolate mofetil (MMF) group of the Chinese trial. None of those SAE was side effect (SE). Most SE in MPS + GC group were mild. Gastrointestinal disorders, infection and liver dysfunction affected 8.8%, 7.1% and 1.2% of all mycophenolate-treated patients (versus 5.4%, 5.4% and 1.2% of all patients on GC monotherapy, respectively). MPS + GC did not significantly increase the risk of infection or liver dysfunction when compared to GC monotherapy. No cytopenia, serious infection or treatment-related mortality was reported. The much higher AE rates of mycophenolate trials in other autoimmune diseases or transplantations suggested that major mycophenolate toxicities were mostly dose- and duration dependent. Mycophenolate, either as monotherapy or as combination, achieved better overall response than GC monotherapy. CONCLUSION: The risk-benefit ratio of low-dose mycophenolate treatment in active moderate-to-severe GO is highly favorable given its reassuring safety profile with low rate of mild-to-moderate SE and promising efficacy.


Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Oftalmopatía de Graves/tratamiento farmacológico , Ácido Micofenólico/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Antibióticos Antineoplásicos/efectos adversos , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Enfermedades Gastrointestinales/inducido químicamente , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Oftalmopatía de Graves/epidemiología , Humanos , Ácido Micofenólico/efectos adversos
3.
J Endocrinol Invest ; 43(2): 123-137, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31538314

RESUMEN

PURPOSE: Immunohistochemistry of orbital tissues offers a correlation between the microscopic changes and macroscopic clinical manifestation of Graves' orbitopathy (GO). Summarizing the participation of different molecules will help us to understand the pathogenesis of GO. METHODS: The pertinent and current literature on immunohistochemistry of human orbital tissue in GO was reviewed using the NCBI PubMed database. RESULTS: 33 articles comprising over 700 orbital tissue samples were included in this review. The earliest findings included the demonstration of HLA-DR and T cell (to a lesser extent B cell) markers in GO orbital tissues. Subsequent investigators further contributed by characterizing cellular infiltration, confirming the presence of HLA-DR and TSHR, as well as revealing the participation of cytokines, growth factors, adhesion molecules and miscellaneous substances. HLA-DR and TSHR are over-expressed in orbital tissues of GO patients. The inflammatory infiltration mainly comprises CD4 + T cells and macrophages. Cytokine profile suggests the importance of Th1 (especially in early active phase) and Th17 immunity in the pathogenesis of GO. Upregulation of proinflammatory/profibrotic cytokines, adhesion molecules and growth factors finally culminate in activation of orbital fibroblasts and perpetuation of orbital inflammation. The molecular status of selected parameters correlates with the clinical presentation of GO. CONCLUSION: Further investigation is warranted to define precisely the role of different molecules and ongoing search for new players yet to be discovered is also important. Unfolding the molecular mechanisms behind GO will hopefully provide insights into the development of novel therapeutic strategies and optimize our clinical management of the disease.


Asunto(s)
Oftalmopatía de Graves/metabolismo , Mediadores de Inflamación/metabolismo , Órbita/química , Órbita/metabolismo , Animales , Linfocitos B/química , Linfocitos B/metabolismo , Citocinas/análisis , Citocinas/metabolismo , Oftalmopatía de Graves/patología , Humanos , Mediadores de Inflamación/análisis , Órbita/patología , Linfocitos T/química , Linfocitos T/metabolismo
4.
J Endocrinol Invest ; 41(1): 91-98, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28819917

RESUMEN

BACKGROUND: In recent years, scientific knowledge pertaining to the rare ORPHAN polyglandular autoimmune syndrome (registered code ORPHA 282196) has accumulated. OBJECTIVE: To offer current demographic, clinical, serological and immunogenic data on PAS. METHODS: Review of the pertinent and current literature. RESULTS: Polyglandular autoimmune syndromes (PAS) are multifactorial diseases with at least two coexisting autoimmune-mediated endocrinopathies. PAS show a great heterogeneity of syndromes and manifest sequentially with a large time interval between the occurrence of the first and second glandular autoimmune disease. PAS cluster with several non-endocrine autoimmune diseases. In most endocrinopathies of PAS, the autoimmune process causes an irreversible loss of function, while chronic autoimmune aggressions can simultaneously modify physiological processes in the affected tissue and lead to altered organ function. The rare juvenile PAS type I is inherited in a monogenetic manner, whereas several susceptibility gene polymorphisms have been reported for the more prevalent adult types. Relevant for a timely diagnosis at an early stage is the screening for polyglandular autoimmunity in patients with monoglandular autoimmune disease and/or first degree relatives of patients with PAS. The most prevalent adult PAS type is the combination of type 1 diabetes with autoimmune thyroid disease. CONCLUSIONS: Early detection of specific autoantibodies and latent organ-specific dysfunction is advocated to alert physicians to take appropriate action in order to prevent full-blown PAS disease.


Asunto(s)
Poliendocrinopatías Autoinmunes/diagnóstico , Adulto , Progresión de la Enfermedad , Humanos , Poliendocrinopatías Autoinmunes/sangre , Poliendocrinopatías Autoinmunes/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA